Dupixent vs Sotyktu
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Dupixent | US Sotyktu | |
|---|---|---|
| Generic name | dupilumab | deucravacitinib |
| Drug class | IL-4/IL-13 Inhibitor (Biologic) | TYK2 Inhibitor |
| Treats | Eczema, asthma, nasal polyps | Plaque psoriasis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Sanofi/Regeneron | Bristol-Myers Squibb |
| Year approved | 2017 | 2022 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $390M | $130M |
| Common side effects | Injection site reactions, Eye inflammation (conjunctivitis), Cold sores, Eosinophilia | Common cold symptoms, Increased infections, Cold sores, Mouth sores |
Frequently asked questions
Is Dupixent or Sotyktu better?
Neither is universally "better." Dupixent (dupilumab) and Sotyktu (deucravacitinib) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Dupixent and Sotyktu?
Dupixent is a IL-4/IL-13 Inhibitor (Biologic) made by Sanofi/Regeneron, while Sotyktu is a TYK2 Inhibitor made by Bristol-Myers Squibb. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Dupixent has the larger estimated TV advertising budget of the two.